Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M.

Clin Lymphoma Myeloma Leuk. 2019 Jan 2. pii: S2152-2650(18)31284-9. doi: 10.1016/j.clml.2018.12.013. [Epub ahead of print]

PMID:
30795996
2.

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK.

Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7.

PMID:
30630772
3.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.

J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.

PMID:
30620669
4.

Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.

Braham MV, Deshantri AK, Minnema MC, Öner FC, Schiffelers RM, Fens MH, Alblas J.

Int J Nanomedicine. 2018 Nov 29;13:8105-8118. doi: 10.2147/IJN.S184262. eCollection 2018.

5.

Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.

Rutten KHG, Raymakers RAP, Hazenberg BPC, Nienhuis HLA, Vellenga E, Minnema MC.

Amyloid. 2018 Dec;25(4):227-233. doi: 10.1080/13506129.2018.1536043. Epub 2018 Dec 4.

PMID:
30513220
6.

MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.

Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Bromberg JEC, Nierkens S, Jiwa NM, Minnema MC, Huibers MMH.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15674. [Epub ahead of print] No abstract available.

PMID:
30408153
7.

CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.

Hiemcke-Jiwa LS, Leguit RJ, Jiwa NM, Huibers MMH, Minnema MC.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15670. [Epub ahead of print] No abstract available.

PMID:
30408147
8.

Clinical management of spinal metastases-The Dutch national guideline.

Bollen L, Dijkstra SPD, Bartels RHMA, de Graeff A, Poelma DLH, Brouwer T, Algra PR, Kuijlen JMA, Minnema MC, Nijboer C, Rolf C, Sluis T, Terheggen MAMB, van der Togt-van Leeuwen ACM, van der Linden YM, Taal W.

Eur J Cancer. 2018 Nov;104:81-90. doi: 10.1016/j.ejca.2018.08.028. Epub 2018 Oct 15. Review.

PMID:
30336360
9.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
10.

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.

Oostvogels R, Jak M, Raymakers R, Mous R, Minnema MC.

Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6.

11.

'Transformation' from amyloid light chain amyloidosis to symptomatic multiple myeloma.

Rutten KHG, Raymakers RAP, Minnema MC.

Neth J Med. 2018 Jul;76(5):249-250.

12.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.

PMID:
29958569
13.

Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.

Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Jiwa NM, Kuiper JJW, de Weger RA, Minnema MC, Huibers MMH.

Crit Rev Oncol Hematol. 2018 Jul;127:56-65. doi: 10.1016/j.critrevonc.2018.05.010. Epub 2018 May 17. Review.

PMID:
29891112
14.

Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.

Braham MVJ, Minnema MC, Aarts T, Sebestyen Z, Straetemans T, Vyborova A, Kuball J, Öner FC, Robin C, Alblas J.

Oncoimmunology. 2018 Feb 22;7(6):e1434465. doi: 10.1080/2162402X.2018.1434465. eCollection 2018.

15.

The Dutch national guideline on metastases and hematological malignancies localized within the spine; a multidisciplinary collaboration towards timely and proactive management.

Groenen KHJ, van der Linden YM, Brouwer T, Dijkstra SPD, de Graeff A, Algra PR, Kuijlen JMA, Minnema MC, Nijboer C, Poelma DLH, Rolf C, Sluis T, Terheggen MAMB, van der Togt-van Leeuwen ACM, Bartels RHMA, Taal W.

Cancer Treat Rev. 2018 Sep;69:29-38. doi: 10.1016/j.ctrv.2018.05.013. Epub 2018 May 29. Review.

16.

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.

van Westrhenen A, Smidt LCA, Seute T, Nierkens S, Stork ACJ, Minnema MC, Snijders TJ.

Br J Haematol. 2018 Aug;182(3):384-403. doi: 10.1111/bjh.15410. Epub 2018 May 29.

17.

Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma.

Braham MVJ, Ahlfeld T, Akkineni AR, Minnema MC, Dhert WJA, Öner FC, Robin C, Lode A, Gelinsky M, Alblas J.

Tissue Eng Part C Methods. 2018 May;24(5):300-312. doi: 10.1089/ten.TEC.2017.0467. Epub 2018 Apr 18.

PMID:
29652626
18.

The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.

Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, de Weger RA, Huibers MMH.

Hematol Oncol. 2018 Apr;36(2):429-435. doi: 10.1002/hon.2489. Epub 2017 Dec 6.

PMID:
29210102
19.

[Unexpected symptoms of monoclonal gammopathy].

Smit PM, Abrahams AC, Schutgens RGE, Notermans NC, Minnema MC.

Ned Tijdschr Geneeskd. 2017;161:D1741. Review. Dutch.

PMID:
29027517
20.

High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.

Vos JM, Notermans NC, D'Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):1007-1009. doi: 10.1136/jnnp-2017-316689. Epub 2017 Oct 10. No abstract available.

PMID:
29018161

Supplemental Content

Loading ...
Support Center